A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
309actual
Sites
82
Countries
Argentina, Australia, Austria +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-05-19 | actual | When the study began enrolling |
| Primary completion | 2018-02-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2016-03-17 | estimated | When this record first appeared on the registry |
| Results posted | 2021-02-26 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Biliary Tract Cancer
- Metastatic Cancer
- Advanced Cancer
Interventions
- Drug: Ramucirumab — also filed as LY3009806
- Drug: Merestinib — also filed as LY2801653
- Drug: Cisplatin
- Drug: Gemcitabine — also filed as LY188011
- Drug: Placebo Oral
- Drug: Placebo IV
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2016-03-30 · 1.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2018-03-19 · 3.4 MB · SAP_001.pdf
Publications
- PMID 34592180 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed